FDA approves Novo Nordisk's diabetes drug: 3 things to know

Written by Mackenzie Bean | December 06, 2017 | Print  |

Novo Nordisk on Tuesday earned FDA approval for its diabetes drug Ozempic.

Here are three things to know.

1. Ozempic is a once-weekly injection used to improve glycemic control in adults with type 2 diabetes.

2. The drug, which will cost $676 per prescription, will directly compete with Eli Lilly's diabetes drug Trulicity, according to Reuters.

3. Novo Nordisk expects Ozempic to hit the market in the first quarter of 2018.

More articles on supply chain:
FDA warns of a new product shortage worsened by Hurricane Maria: 4 things to know
Gilead launches hepatitis drug in China at one-fifth the US price
CVS launches 'real-time benefits' tool to increase price transparency

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.